Your Guide To Navigating Perimenopause In Your 30s And Beyond
And I'm not alone. When I set out to report on this often overlooked and misunderstood phase of life, nearly a dozen women I spoke to initially had zero clue that perimenopause could be the root of their sudden and varied symptoms. They also had no idea it can last anywhere from two to 10 years (sometimes more), it's characterized by a fluctuation of hormones (not necessarily a sharp decline), and, perhaps most significantly, it can start as early as your mid-thirties (I couldn't believe it either).
The good news is there's more awareness than ever around perimenopause, thanks to a growing call for menopause education, millennials' track record of breaking taboos, and a little thing called the social media algorithm. And we hope this series of stories, below, contributes to that. You'll find a special report on millennials and perimenopause, real stories from women on how they successfully manage their peri symptoms, hormonal and non-hormonal treatment options, where to actually find good care, tips on how to stay healthy in peri and beyond, and how to advocate for menopause policy in your state.
Our grandmothers and mothers may not have had the word to describe this phase of life, but we do. And the more prepared we are for it, the better (and healthier) we are. Read the stories, share them with your friends, and let us know what you think in the comments—this is only the beginning of the conversation.
Read The StoriesMillennials Are Entering The Perimenopause Chat
READ THE STORYYour Brain (And Heart) On Hot Flashes
READ THE STORYHow Young Is Too Young For Hormone Therapy?
READ THE STORYHow These Women Are Successfully Managing Their Perimenopause Symptoms
READ THE STORYWhere To Actually Find Good Perimenopause Care
READ THE STORYHow To Stay Healthy In Perimenopause And Beyond
READ THE STORYWe Need To Fight For Menopause Policy Now More Than Ever
READ THE STORY
This story appears in the Summer 2025 issue of Women's Health.Photographs By Heami LeeProp Styling By Christine Keely
You Might Also Like
Jennifer Garner Swears By This Retinol Eye Cream
These New Kicks Will Help You Smash Your Cross-Training Goals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News
July 28 - Atai Life Sciences (NASDAQ:ATAI) shares slid 9% in pre?market trading on Monday after Recognify Life Sciences, an Atai?backed company, reported its Phase 2b trial of inidascamine for cognitive impairment linked to schizophrenia missed its primary endpoint. Warning! GuruFocus has detected 6 Warning Signs with ATAI. The oral compound, engineered to modulate multiple neurotransmitter pathways for pro?cognitive effects, failed to outperform placebo on key cognitive measures. Recognify said the results fell short of statistical significance. Atai's CEO acknowledged the setback but highlighted inidascamine's potential in CIAS and other indications. He added that Atai will redirect its efforts toward its wholly?owned psychedelic programs focused on affective disorders. Investors have been closely watching Atai's broader pipeline, which includes compounds targeting depression, PTSD and Alzheimer's disease. This latest trial disappointment adds to a string of mid?stage readouts that have tested market sentiment around biotech firms pivoting to next?generation neuroscience therapies. Despite today's drop, Atai's management reiterated its commitment to advancing its lead psychedelic candidates through upcoming Phase 1 and Phase 2 trials. Based on the one year price targets offered by 6 analysts, the average target price for ATAI Life Sciences NV is $9.83 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies a upside of +175.44% from the current price of $3.57. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Parents call on FDA for path forward after Duchenne's gene therapy pause
The Food and Drug Administration has paused distribution of the gene therapy Elevidys following the death of a third patient receiving treatment for muscular dystrophy. Alison and William Small are urging the agency to restore access to the drug, the only FDA-approved treatment for Duchenne's muscular dystrophy. Speaking to 'Morning in America,' the Smalls call for transparency and a clear path forward from federal regulators. They say families affected by Duchenne's deserve to understand the risks and that many believe the treatment is worth fighting for. Solve the daily Crossword
Forbes
15 minutes ago
- Forbes
OpenEvidence's Meteoric Rise Is Huge For Doctors
Medical research and science has never been easier to access. OpenEvidence has raised hundreds of millions of dollars. In its most recent funding round, it raised a $210 million Series B from prominent investors such as Google Ventures and Kleiner Perkins, bringing the company's valuation to nearly $3.5 billion. The company's goal is straightforward and incredibly ambitious: to collate the entire corpus of medical knowledge and research developments in a way that is easily accessible to physicians and thereby, improve health outcomes. The service is aiming to provide a similar 'touch and feel' as other generative AI services such as Chat GPT or Google's Gemini—except, its target audience is primarily doctors. Medical science is a rapidly evolving field with a perpetually expanding sea of knowledge, especially as research and development across the fields of disease, therapeutics and human sciences continue to grow. In fact, as Sequoia Capital notes, 'a new PubMed article [which is often the flagship resource for peer-reviewed science studies]The value of this type of technology is increasingly being recognized. The latest models for OpenAI's ChatGPT (GPT 4.1 and o3) have displayed incredible efficacy in taking command of medical knowledge; in May, the company published its work with HealthBench, proposing a rubric for model performance in healthcare and also indicating that GPT's latest models performed at par or even better than standard physician evaluations. Even Google's Gemini family of models has made significant progress in this space; its MedLM suite, for example, is a highly tuned model that can aid the entire healthcare workflow, ranging from answering medical questions to deciphering unstructured health data. Why is all of this important? There are a few different reasons. First and foremost, this technology is aiming to democratize medical knowledge in a way that is easy to access. Furthermore, it comes at a time when the healthcare system, and its respective workforce, is facing unprecedented headwinds. Studies have repeatedly indicated that physician burnout and attrition are incredibly concerning problems for health systems and organizations of all sizes; physicians simply do not have the bandwidth to fulfill all of their patient care duties in addition to the increasingly prevalent administrative, compliance and regulatory burdens placed on them. This also means that there is less time for professional development and continuing education. These technologies can serve as a major advantage to the physician workflow as they provide an opportunity to easily query, fact-check and understand the latest science that is involved with a condition. Carry this even further with tools such as OpenEvidence DeepConsult, which gives physicians access to PhD-level AI agents that can conduct medical research, or Gemini's foundation models that can rapidly decipher medical images, or even AI scribing technology that can rapidly generate patient-physician encounter notes, and soon, hours can be saved from a physician's daily workflow. This translates not only to millions of dollars saved annually in system costs, but also to more time available to spend with patients, improved access to care, and ultimately, increased efficacy and quality of care provided.
